Restricted stock

Adamas Announces New Employment Inducement Grant

Retrieved on: 
금요일, 6월 11, 2021
Biotechnology, Pharmaceutical, Health, Other Health, Financial markets, Corporate finance, Stock market, Finance, Financial economics, Stock, Restricted stock

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the companys board of directors granted three new employees restricted stock units to acquire 22,500 shares of the companys common stock.

Key Points: 
  • Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the companys board of directors granted three new employees restricted stock units to acquire 22,500 shares of the companys common stock.
  • The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
  • At Adamas our vision is clear to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society.
  • We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.

Energous Corporation Grants Inducement Restricted Stock Units to New Employee

Retrieved on: 
화요일, 6월 8, 2021
Mobile, Wireless, Technology, Hardware, Financial markets, Finance, Corporate finance, Money, Stock market, Employee stock ownership, Fundamental analysis, Restricted stock, NASDAQ, Stock, Inductive charging, RSU

Energous Corporation (Nasdaq: WATT), the developer of WattUp, a revolutionary wireless charging 2.0 technology, today announced it has issued inducement restricted stock units (RSUs) to one new non-executive employee.

Key Points: 
  • Energous Corporation (Nasdaq: WATT), the developer of WattUp, a revolutionary wireless charging 2.0 technology, today announced it has issued inducement restricted stock units (RSUs) to one new non-executive employee.
  • On May 13 , 2021, one new non-executive employee was issued RSUs covering a total of 7,000 shares of common stock under the Companys 2017 Equity Inducement Plan (the Inducement Plan).
  • Each RSU is subject to the terms and conditions of the Inducement Plan and the terms and conditions of the respective award agreement covering each granted RSU.
  • Energous Corporation (Nasdaq: WATT) is the global leader of Wireless Charging 2.0 technology.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
금요일, 6월 4, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Puma Biotechnology, Financial markets, Puma, Restricted stock, Companies, Finance

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2021, the Compensation Committee of Pumas Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 30,375 shares of Puma common stock to five new non-executive employees.

Key Points: 
  • Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2021, the Compensation Committee of Pumas Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 30,375 shares of Puma common stock to five new non-executive employees.
  • The award was granted under Pumas 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma.
  • The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
금요일, 6월 4, 2021
Financial markets, Finance, Money, Corporate finance, Stock market, Employee stock ownership, Fundamental analysis, Restricted stock, Flexion Therapeutics, NASDAQ, Stock, Executive compensation

BURLINGTON, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 8,510 restricted stock units.

Key Points: 
  • BURLINGTON, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 8,510 restricted stock units.
  • The Compensation Committee of the Board of Directors approved the grants with an effective date of June 1, 2021.
  • The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units are subject to the terms and conditions of the Company's 2013 Equity Incentive Plan and a restricted stock unit agreement covering the grant.

Surgalign Holdings, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Retrieved on: 
금요일, 6월 4, 2021
Finance, Financial markets, Money, Corporate finance, Contract law, Employee stock ownership, Fundamental analysis, Restricted stock, Stock market, Executive compensation, Option, NASDAQ

The awards were granted on June 1, 2021 under the Surgalign Holdings, Inc. 2021 Inducement Plan, and include 116,751 options with an exercise price of $1.80 and 62,916 restricted stock units.

Key Points: 
  • The awards were granted on June 1, 2021 under the Surgalign Holdings, Inc. 2021 Inducement Plan, and include 116,751 options with an exercise price of $1.80 and 62,916 restricted stock units.
  • The awards were approved by the independent Compensation Committee of the Board of Directors of Surgalign Holdings and were granted to the new employees as an inducement material to their acceptance of employment with Surgalign pursuant to Nasdaq rules.
  • Surgalign is focused on bringing surgeons solutions that predictably deliver superior clinical and economic outcomes.
  • Surgalign markets products throughout the United States and in more than 50 countries worldwide through an expanding network of top independent distributors.

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
금요일, 6월 4, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Corporate finance, Employee stock ownership, Fundamental analysis, Restricted stock, Stock market, Labour law, Finance, Vesting, Urology, RSU, Law, Private law

UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units (RSUs) to eleven new employees in connection with their employment with UroGen.

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units (RSUs) to eleven new employees in connection with their employment with UroGen.
  • Up to 46,100 shares of UroGens common stock are issuable upon the vesting and settlement of the RSUs.
  • The RSUs are subject to the terms and conditions of UroGens 2019 Inducement Plan and RSU grant notice and agreement thereunder.
  • The RSU grants were granted as an inducement material to each employee entering into employment with UroGen in accordance with Nasdaq listing Rule 5635(c)(4).

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
금요일, 5월 28, 2021
Financial markets, Finance, Financial economics, Corporate finance, Stock market, Employee stock ownership, Fundamental analysis, Restricted stock, Stock, Futures contract, NASDAQ, Short

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 6,295 shares of Sarepta's common stock, and in the aggregate 2,950 restricted stock units (RSUs).
  • Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short.
  • We encourage investors and potential investors to consult our website regularly for important information about us.

Synchronoss Technologies, Inc. Reports Inducement Grants to Employees Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
목요일, 5월 27, 2021
Corporate governance, Executive compensation, Recruitment, Restricted stock, Corporations, Economy

Each of these grants was an inducement award that was approved by the Compensation Committee of Synchronoss Board of Directors and granted as an inducement equity award under the Company's 2017 New Hire Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • Each of these grants was an inducement award that was approved by the Compensation Committee of Synchronoss Board of Directors and granted as an inducement equity award under the Company's 2017 New Hire Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Synchronoss granted the four newly hired employees an aggregate of 4,838 time-based restricted stock awards.
  • Synchronoss Technologies (NASDAQ: SNCR) builds software that empowers companies around the world to connect with their subscribers in trusted and meaningful ways.
  • Thats why more than 1,500 talented Synchronoss employees worldwide strive each day to reimagine a world in sync.

Pacific Biosciences Grants Equity Incentive Award to New Employee

Retrieved on: 
금요일, 5월 21, 2021
Biology, Branches of biology, Life sciences, Molecular biology, Biotechnology, DNA sequencing, DNA, Pacific Biosciences, Third-generation sequencing, XC2, SMRT, Restricted stock

The RSUs shall be scheduled to vest as to 1/4th of the total number of shares subject at grant to the RSUs on each of the one (1), two (2), three (3), and four (4) year anniversaries of the Effective Date.

Key Points: 
  • The RSUs shall be scheduled to vest as to 1/4th of the total number of shares subject at grant to the RSUs on each of the one (1), two (2), three (3), and four (4) year anniversaries of the Effective Date.
  • The option grant and the award of restricted stock units are subject to the terms and conditions of the 2020 Inducement Plan and the award agreements entered into with the non-executive officer employee.\nPacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing.
  • The company\xe2\x80\x99s innovative instruments are based on Single Molecule, Real-Time (SMRT\xc2\xae) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism.
  • Cited in thousands of peer-reviewed publications, PacBio\xc2\xae sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.\n'

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
금요일, 5월 7, 2021
Financial markets, Finance, Financial economics, Corporate finance, Stock market, Flexion Therapeutics, Stock, Executive compensation, Restricted stock, NASDAQ

b"BURLINGTON, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to eight new employees consisting of 18,200 restricted stock units.

Key Points: 
  • b"BURLINGTON, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to eight new employees consisting of 18,200 restricted stock units.
  • The Compensation Committee of the Board of Directors approved the grants with an effective date of May 3, 2021.
  • The company's core values are focus, ingenuity, tenacity, transparency and fun.
  • Please visit flexiontherapeutics.com .\n"